EODData

OTCBB, DSNKY: Daiichi Sankyo Ltd ADR

17 Nov 2025
LAST:

22.15

CHANGE:
 0.39
OPEN:
21.60
HIGH:
23.18
ASK:
0.00
VOLUME:
459.0K
CHG(%):
1.73
PREV:
22.54
LOW:
21.60
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
17 Nov 2521.6023.1821.6022.15459.0K
14 Nov 2521.7822.6521.7822.54257.7K
13 Nov 2522.2522.5721.6621.73669.7K
12 Nov 2523.0023.0022.2322.50277.1K
11 Nov 2522.0722.1121.8522.11540.5K
10 Nov 2522.2222.2221.2221.45582.7K
07 Nov 2522.0022.0021.7521.94187.8K
06 Nov 2523.0623.0622.0622.14456.2K
05 Nov 2521.8822.4021.8822.22223.4K
04 Nov 2522.0022.1821.8821.88273.2K

PROFILE

Name:Daiichi Sankyo Ltd ADR
About:Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection to treat iron deficiency; and DATROWAY to treat adult patients with hormone receptor (HR) positive, and HER2 negative. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.
Sector:Healthcare
Address:3-5-1, Nihonbashi-honcho, Tokyo, Japan, 103-8426
Website:https://www.daiichisankyo.com
ISIN:US23381D1028
FIGI:BBG0027W0079

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:24.05 
Forward P/E:21.93 
Price to Sales:0.02 
Price to Book:4.26 
DivYield:0.02 
Div/Share:60.00 
Revenue:1,924.678B 
EBITDA:405.494B 
Shares:1.863B 
Market Cap:41.258B 

TECHNICAL INDICATORS

MA5:22.210.3%
MA10:22.070.4%
MA20:23.928.0%
MA50:24.4210.3%
MA100:24.269.5%
MA200:24.269.5%
STO9:40.46
STO14:16.51 
RSI14:25.70 
WPR14:-82.50 
MTM14:-3.30
ROC14:-0.13 
ATR:1.10 
Week High:23.184.7%
Week Low:21.224.4%
Month High:27.5024.2%
Month Low:21.229.5%
Year High:33.2149.9%
Year Low:20.925.9%
Volatility:11.56 

RECENT SPLITS

Date Ratio
09 Oct 20203-1